Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 37 and last traded at GBX 39.60, with a volume of 7358 shares trading hands. The stock had previously closed at GBX 41.
Faron Pharmaceuticals Oy Trading Down 3.4%
The firm has a market cap of £80.34 million, a price-to-earnings ratio of -1.79 and a beta of 1.12. The company’s 50-day moving average price is GBX 41.79 and its 200-day moving average price is GBX 54.42. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
